+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid



Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid



Clinical and Experimental Allergy 31(10): 1607-1614



The cause and pathogenesis of chronic urticaria are still poorly understood. IgE-independent reactions, are common in adult patients with chronic urticaria, who have daily spontaneous occurrence of weals. H(1)-receptor antagonists (antihistamines) are the major class of therapeutic agents used in the management of urticaria and angioedema. Nevertheless, chronic urticaria is often difficult to treat and may not be controlled by antihistamines alone. It has been postulated that mediators other than histamine, such as kinins, prostaglandin and leukotrienes, may be responsible for some of the symptoms in urticaria which are not controlled by antihistamines. In this study, which was randomized double-blind, placebo-controlled, we compare the clinical efficacy and safety of montelukast (MT) 10 mg given once a day and cetirizine (CET) 10 mg given once a day with placebo (PLA), in the treatment of patients with chronic urticaria who have positive challenge to acetylsalicylic acid (ASA) and/or food additives. A group of 51 patients, ranging in age from 15 to 71 years, with chronic urticaria and positive challenge to food additives and/or ASA, participated in this study for a period of 4 weeks, starting from a 3-day run-in. The assessment of the efficacy was based on scores of daily urticaria symptoms. MT significantly increased the percentage of symptom-free days for hive and itch. Analysis of frequency distribution of urticaria scores for each symptom gave similar results (MT vs. CET and MT vs. PLA, P < 0.001). The interference with sleep due to their skin condition was also lower in the group treated with MT (P < 0.001). In addition, the median number of days without the rescue medication was significantly higher in the MT group (24 days) than both the CET and the PLA groups (18 days, P < 0.001, and 20 days, P < 0.001, respectively). Finally, a low incidence of adverse events was observed in this study. The results of this comparative study demonstrate that montelukast orally administered once a day is very effective for the treatment of cutaneous symptoms in patients with chronic urticaria due to food additives and/or ASA.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 003430616

Download citation: RISBibTeXText

PMID: 11678862

DOI: 10.1046/j.1365-2222.2001.01189.x


Related references

The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: A single-blind, placebo-controlled, crossover clinical study. Journal of Allergy & Clinical Immunology 110(3): 484-488, 2002

Safety and efficacy of cetirizine versus cetirizine plus ranitidine in chronic urticaria: Double-blind randomized placebo-controlled study. Journal of Dermatological Treatment 26(6): 548-550, 2016

Double blind placebo controlled comparison of cetirizine and terfenadine in chronic idiopathic urticaria. Acta Therapeutica 15(1): 77-86, 1989

A comparison of the efficacy of cetirizine and terfenadine: A double-blind, controlled study of chronic idiopathic urticaria. Allergy 48(5): 358-365, 1993

Double-blind, parallel, randomized pilot study comparing the efficacy and tolerance of cetirizine 10 mg, mequitazine 2 X 5 mg and placebo in the treatment of patients suffering from chronic urticaria: Comparison of suppressive effects on histamine-induced weals and flares. Drug Development Research 43(4): 185-192, 1998

Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clinical and Experimental Allergy 34(9): 1401-1407, 2004

Theophylline as 'add-on' therapy to cetirizine in patients with chronic idiopathic urticaria. A randomized, double-blind, placebo-controlled pilot study. International Archives of Allergy and Immunology 139(3): 258-264, 2006

Efficacy of montelukast, a leukotriene receptor antagonist, for the treatment of dysmenorrhea: a prospective, double-blind, randomized, placebo-controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology 148(2): 195-198, 2010

Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial. Journal of the American Academy of Dermatology 33(2 PART 1): 192-198, 1995

Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 65(4): 516-528, 2010

Chronic idiopathic urticaria Evaluation of the efficacy and tolerance of the Cetirizine versus Terfenadine and Placebo Study of double blind. Journal of Allergy & Clinical Immunology 95(1 PART 2): 253, 1995

Efficacy of the eradication of Helicobacter pylori infection in patients with chronic urticaria. A placebo-controlled double blind study. Allergologia et Immunopathologia 30(5): 255-258, 2002

Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. Journal of the American Academy of Dermatology 48(4): 535-541, 2003

Acetylsalicylic acid--additive intolerance phenomenon in chronic recurring urticaria. Dermatologische Monatschrift 168(8): 513-519, 1982

Treatment of chronic urticaria with Zafirluklast A double-blind, placebo-controlled cross-over study on 46 patients. Allergy 56(Supplement 68): 149-150, 2001